{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:54:06Z","timestamp":1791525246776,"version":"4.3.4"},"reference-count":77,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Celgene, a Bristol Myers Squibb company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Multi-agent regimens incorporating immunomodulatory (IMiD\u00ae) agents such as thalidomide, lenalidomide, and pomalidomide have become the preferred standard of care for the treatment of patients with multiple myeloma (MM), resulting in improved survival outcomes. Currently, there are three IMiD agents approved for the treatment of MM: thalidomide, lenalidomide, and pomalidomide. Lenalidomide is commonly used to treat patients with newly diagnosed MM and as maintenance therapy following stem cell transplant or after disease relapse. Pomalidomide, the focus of this review, is approved in patients with relapsed\/refractory MM (RRMM). Despite survival benefits, IMiD agents each have different safety profiles requiring consideration both prior to starting therapy and during treatment. Adverse event (AE) management is essential, not only to ensure treatment adherence and thus ensure optimal efficacy but also to maintain patient quality of life. Here, we discuss AEs associated with pomalidomide and present five clinically relevant hypothetical case studies in patients with RRMM to provide scenario-driven guidance regarding treatment selection and AE prevention and management in the clinical setting. Lastly, as new treatment approaches continue to be explored in MM, we also discuss novel cereblon E3 ligase modulator (CELMoD\u2122) agents including iberdomide (CC-220) and mezigdomide (CC-92480).<\/jats:p>","DOI":"10.3390\/cancers16051023","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T03:31:23Z","timestamp":1709263883000},"page":"1023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.3390","volume":"16","author":[{"given":"Omar","family":"Nadeem","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Catamero","sequence":"additional","affiliation":[{"name":"Mount Sinai Hospital, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1075-0959","authenticated-orcid":false,"given":"Kathryn","family":"Maples","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Greco-Hainsworth Centers for Cancer Research, Tennessee Oncology, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"ref_2","unstructured":"(2024, January 11). THALOMID\u00ae (thalidomide). Celgene, a Bristol-Myers Squibb Company. Thalidomide Prescribing Information. Available online: https:\/\/packageinserts.bms.com\/pi\/pi_thalomid.pdf."},{"key":"ref_3","unstructured":"REVLIMID\u00ae (Lenalidomide) (2023). [Prescribing Information], Celgene, a Bristol-Myers Squibb Company."},{"key":"ref_4","unstructured":"(2024, January 11). POMALYST\u00ae (pomalidomide). Celgene, a Bristol-Myers Squibb Company. Pomalidomide Prescribing Information. Available online: https:\/\/packageinserts.bms.com\/pi\/pi_pomalyst.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Weisel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","article-title":"Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment","volume":"34","author":"Siegel","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Charlinski, G., Vesole, D.H., and Jurczyszyn, A. (2021). Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers, 13.","DOI":"10.3390\/cancers13184666"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed\/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1756-8722-6-41","article-title":"A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma: The MM-021 trial","volume":"6","author":"Hou","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: An overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: A randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2014.248","article-title":"Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma","volume":"28","author":"Usmani","year":"2014","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Balmaceda, N., Aziz, M., Chandrasekar, V.T., McClune, B., Kambhampati, S., Shune, L., Abdallah, A.O., Anwer, F., Majeed, A., and Qazilbash, M. (2021). Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08451-x"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"989032","DOI":"10.3389\/fphar.2022.989032","article-title":"Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): Follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1182\/bloodadvances.2022008866","article-title":"Phase 1\/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma","volume":"7","author":"Derman","year":"2023","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"ref_25","unstructured":"Bristol Myers Squibb (2022). Imnovid\u00ae (pomalidomide) Summary of Product Characteristics, European Medicines Agency."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kumar, S., Nair, S., Lin, X., Marshall, A., Slavcev, M., Potluri, R., and Chari, A. (2022, January 25\u201327). Treatment patterns and outcomes of patients with triple-class exposed relapsed or refractory multiple myeloma: Analysis of the Optum electronic health records and commercial claims database. Proceedings of the 19th International Myeloma Society Annual Meeting, Los Angeles, CA, USA.","DOI":"10.1016\/S2152-2650(22)00595-X"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/BLCTT.S91251","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","article-title":"Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network","volume":"32","author":"Ludwig","year":"2018","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/EDBK_205443","article-title":"Practical Considerations for Antibodies in Myeloma","volume":"38","author":"Laubach","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-related fatigue, version 2.2015","volume":"13","author":"Berger","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lancet Respiratory Medicine (Editorial) (2020). Time to wake the giant of obstructive sleep apnoea. Lancet Respir. Med., 8, 1.","DOI":"10.1016\/S2213-2600(19)30449-7"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1182\/blood-2017-01-725705","article-title":"How I manage the toxicities of myeloma drugs","volume":"129","author":"Delforge","year":"2017","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Del Giudice, M.L., Gozzetti, A., Antonioli, E., Orciuolo, E., Ghio, F., Ciofini, S., Candi, V., Fontanelli, G., Attucci, I., and Formica, G. (2021). Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. Medicina, 57.","DOI":"10.3390\/medicina57090900"},{"key":"ref_34","first-page":"293","article-title":"Tolerability and safety of real-world use of pomalidomide in patients with relapsed\/refractory multiple myeloma","volume":"10","author":"Usami","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: A population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","article-title":"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy","volume":"98","author":"Zangari","year":"2001","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.thromres.2008.09.008","article-title":"Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy","volume":"123","author":"Musallam","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.4065\/80.12.1568","article-title":"The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma","volume":"80","author":"Baz","year":"2005","journal-title":"Mayo Clin. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00432-021-03693-5","article-title":"Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: A real-life study","volume":"148","author":"Leclerc","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2018-99-111906","article-title":"Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study","volume":"132","author":"Abildgaard","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.4149\/neo_2022_220813N827","article-title":"Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients: Czech registry data","volume":"69","author":"Sandecka","year":"2022","journal-title":"Neoplasma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/leu.2011.126","article-title":"Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bahlis, N., Schiller, G., Samaras, C., Sebag, M., Berdeja, J., Ganguly, S., Matous, J., Song, K., Seet, C., and Bar, M. (2022, January 25\u201327). Adverse event patterns and management with pomalidomide, dexamethasone, and daratumumab in patients with relapsed or refractory multiple myeloma: A safety analysis of the phase 2 MM-014 study. Proceedings of the 19th International Myeloma Society Annual Meeting, Los Angeles, CA, USA.","DOI":"10.1016\/S2152-2650(22)00562-6"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2021-151161","article-title":"Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and\/or Refractory Multiple Myeloma (RRMM) Patients","volume":"138","author":"Joseph","year":"2021","journal-title":"Blood"},{"key":"ref_46","unstructured":"(2015). Pomalidomide. Aust. Prescr., 38, 31\u201332."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1188\/17.CJON.S5.7-18","article-title":"Distress, Fatigue, and Sexuality: Understanding and Treating Concerns and Symptoms in Patients With Multiple Myeloma","volume":"21","author":"Catamero","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood.V124.21.4754.4754","article-title":"Effect of renal and hepatic function on pomalidomide dose in patients with relapsed\/refractory multiple myeloma","volume":"124","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3324\/haematol.2015.137083","article-title":"Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low-dose dexamethasone versus high-dose dexamethasone in refractory or relapsed and refractory multiple myeloma","volume":"101","author":"Weisel","year":"2016","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10157-018-1641-8","article-title":"Clinical epidemiology of infectious disease among patients with chronic kidney disease","volume":"23","author":"Ishigami","year":"2019","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: Risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"Larocca","year":"2022","journal-title":"Haematologica"},{"key":"ref_59","unstructured":"(2024, January 11). XARELTO\u00ae (rivaroxaban). Jenssen. Rivaroxaban Prescribing Information. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CMAR.S27087","article-title":"Lenalidomide for the treatment of relapsed and refractory multiple myeloma","volume":"4","author":"Gorgun","year":"2012","journal-title":"Cancer Manag. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","article-title":"The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience","volume":"18","author":"Zafar","year":"2013","journal-title":"Oncologist"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","article-title":"Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes","volume":"17","author":"Smith","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2021-148068","article-title":"CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma","volume":"138","author":"Carrancio","year":"2021","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1182\/blood-2022-157939","article-title":"Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing","volume":"140","author":"Gaffney","year":"2022","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"CT186","DOI":"10.1158\/1538-7445.AM2022-CT186","article-title":"Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1\/3 degrader, CFT7455, enables significant potency advantage over other IKZF1\/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1\/2 study of CFT7455 in MM","volume":"82","author":"Lonial","year":"2022","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Mendy","year":"2012","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1126\/science.add7574","article-title":"Molecular glue CELMoD compounds are regulators of cereblon conformation","volume":"378","author":"Watson","year":"2022","journal-title":"Science"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): A multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","article-title":"Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma","volume":"389","author":"Richardson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2021-153575","article-title":"A phase 1 study of CFT7455, a novel degrader of IKZF1\/3, in multiple myeloma and non-Hodgkin lymphoma","volume":"138","author":"Berdeja","year":"2021","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Gengenbach, L., Graziani, G., Reinhardt, H., R\u00f6sner, A., Braun, M., M\u00f6ller, M.-D., Greil, C., W\u00e4sch, R., and Engelhardt, M. (2021). Choosing the Right Therapy for Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related Factors. Cancers, 13.","DOI":"10.3390\/cancers13174320"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/leu.2017.156","article-title":"Spotlight on pomalidomide: Could less be more?","volume":"31","author":"Zander","year":"2017","journal-title":"Leukemia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/1023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:31Z","timestamp":1760105251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/1023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16051023"],"URL":"https:\/\/doi.org\/10.3390\/cancers16051023","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}